Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease associated with motor neuron degeneration, muscle atrophy and paralysis. To date, multiple panels of biomarkers have been described in ALS patients and murine models. Nevertheless, none of them has sufficient specificity and thus the molecular signature for ALS prognosis and progression remains to be elucidated. Here we overcome this limitation through a longitudinal study, analyzing serum levels of circulating miRNAs, stable molecules that are recently used as promising biomarkers for many types of human disorders, in ALS patients during the progression of the pathology. We performed next-generation sequencing (NGS) analysis and absolute RT quantification of serum samples of ALS patients and healthy controls. The expression levels of five selected miRNAs were quantitatively analyzed during disease progression in each patient and we demonstrated that high levels of miR-206, miR-133a and miR-151a-5p can predict a slower clinical decline of patient functionality. In particular, we found that miR-206 and miR-151a-5p serum levels were significantly up-regulated at the mild stage of ALS pathology, to decrease in the following moderate and severe stages, whereas the expression levels of miR-133a and miR-199a-5p remained low throughout the course of the disease, showing a diagnostic significance in moderate and severe stages for miR-133a and in mild and terminal ones for miR-199a-5p. Moreover, we found that miR-423-3p and 151a-5p were significantly downregulated respectively in mild and terminal stages of the disease. These data suggest that these miRNAs represent potential prognostic markers for ALS disease.

A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients / Dobrowolny, Gabriella; Martone, Julie; Lepore, Elisa; Casola, Irene; Petrucci, Antonio; Inghilleri, Maurizio; Morlando, Mariangela; Colantoni, Alessio; Scicchitano, Bianca Maria; Calvo, Andrea; Bisogni, Giulia; Chiò, Adriano; Sabatelli, Mario; Bozzoni, Irene; Musarò, Antonio. - In: CELL DEATH DISCOVERY. - ISSN 2058-7716. - 7:1(2021), p. 4. [10.1038/s41420-020-00397-6]

A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients

Dobrowolny, Gabriella
Co-primo
;
Martone, Julie
Co-primo
;
Lepore, Elisa;Casola, Irene;Petrucci, Antonio;Inghilleri, Maurizio;Morlando, Mariangela;Colantoni, Alessio;Scicchitano, Bianca Maria;Bozzoni, Irene;Musarò, Antonio
Ultimo
2021

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease associated with motor neuron degeneration, muscle atrophy and paralysis. To date, multiple panels of biomarkers have been described in ALS patients and murine models. Nevertheless, none of them has sufficient specificity and thus the molecular signature for ALS prognosis and progression remains to be elucidated. Here we overcome this limitation through a longitudinal study, analyzing serum levels of circulating miRNAs, stable molecules that are recently used as promising biomarkers for many types of human disorders, in ALS patients during the progression of the pathology. We performed next-generation sequencing (NGS) analysis and absolute RT quantification of serum samples of ALS patients and healthy controls. The expression levels of five selected miRNAs were quantitatively analyzed during disease progression in each patient and we demonstrated that high levels of miR-206, miR-133a and miR-151a-5p can predict a slower clinical decline of patient functionality. In particular, we found that miR-206 and miR-151a-5p serum levels were significantly up-regulated at the mild stage of ALS pathology, to decrease in the following moderate and severe stages, whereas the expression levels of miR-133a and miR-199a-5p remained low throughout the course of the disease, showing a diagnostic significance in moderate and severe stages for miR-133a and in mild and terminal ones for miR-199a-5p. Moreover, we found that miR-423-3p and 151a-5p were significantly downregulated respectively in mild and terminal stages of the disease. These data suggest that these miRNAs represent potential prognostic markers for ALS disease.
2021
ALS, circulating microRNAs, biomarkers
01 Pubblicazione su rivista::01a Articolo in rivista
A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients / Dobrowolny, Gabriella; Martone, Julie; Lepore, Elisa; Casola, Irene; Petrucci, Antonio; Inghilleri, Maurizio; Morlando, Mariangela; Colantoni, Alessio; Scicchitano, Bianca Maria; Calvo, Andrea; Bisogni, Giulia; Chiò, Adriano; Sabatelli, Mario; Bozzoni, Irene; Musarò, Antonio. - In: CELL DEATH DISCOVERY. - ISSN 2058-7716. - 7:1(2021), p. 4. [10.1038/s41420-020-00397-6]
File allegati a questo prodotto
File Dimensione Formato  
Dobrowolny_A longitudinal study_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.66 MB
Formato Adobe PDF
1.66 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1475228
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 28
social impact